Dr. Qandeel Hayat, Dr Kulsoom Ejaz, Dr. Adeel Ahmed
Objective: The aim of the research was to draw a comparison of safety and efficacy of the total dose infusion profile iron dextran (low molecular weight) against distributed intravenous iron sucrose doses to manage pregnant women diagnosed with iron deficiency anaemia. Patients and Methods: This research was a randomized control trial which was carried out at Mayo Hospital, Lahore from October 2017 to November 2018. We distributed the sample that consisted of pregnant women with a gestational age of (> 12 weeks) and these women were confirmed for Iron Deficiency Anemia (IDA). We managed Group – A with intravenous iron sucrose and iron dextran (low molecular weight) to Group – B. was given. We confirmed Post-infusion Hemoglobin (Hb) at the fourth week and at delivery. Pre to post Hb rise comparison was made through paired T-Test which was not significant. Results: Mean Hb pre-infusion level for Group – A, mean increase and after four weeks of infusion were respectively (9.09 ± 0.83) gm/dl, (10.75 ± 1.097) gm/dl and (11.06 ± 0.866) gm/dl at delivery with a significant P-Value under 0.001. Mean Hb pre-infusion in Group – B was (8.735 ± 0.956) gm/dl, mean Hb increase at fourth week was (10.613 ± 1.22) gm/dl; whereas, an increase at the time of delivery was (10.859 ± 1.11) gm/dl (P-Value < 0.001). Conclusion: Both iron sucrose and iron dextran (LMW) were equally effective for the management of IDA among pregnant women; however, the later has an advantage that there is no need for the second visit for the treatment of IDA as it manages the onset of IDA at the first visit. Keywords: Pregnancy, Anemia, Iron Deficiency Anemia (IDA), Iron, Parental, Dextran, LMW (Low Molecular Weight) and Sucrose.